The tumor suppressor activity of the BRCA1 gene product is due, in part, to functional interactions with other tumor suppressors, including p53 and the retinoblastoma (RB) protein. RB binding sites on BRCA1 were identi®ed in the C-terminal BRCT domain (Yarden and Brody, 1999) and in the N-terminus (aa 304 ± 394) (Aprelikova et al., 1999) . The N-terminal site contains a consensus RB binding motif, LXCXE (aa 358 ± 362), but the role of this motif in RB binding and BRCA1 functional activity is unclear. In both in vitro and in vivo assays, we found that the BRCA1:RB interaction does not require the BRCA1 LXCXE motif, nor does it require an intact A/B binding pocket of RB. In addition, nuclear co-localization of the endogenous BRCA1 and RB proteins was observed. Over-expression of wild-type BRCA1 (wtBRCA1) did not cause cell cycle arrest but did cause down-regulation of expression of RB, p107, p130, and other proteins (e.g., p300), associated with increased sensitivity to DNA-damaging agents. In contrast, expression of a full-length BRCA1 with an LXCXE inactivating mutation (LXCXE?RXRXH) failed to down-regulate RB, blocked the down-regulation of RB by wtBRCA1, induced chemoresistance, and abrogated the ability of BRCA1 to mediate tumor growth suppression of DU-145 prostate cancer cells. wtBRCA1-induced chemosensitivity was partially reversed by expression of either Rb or p300 and fully reversed by co-expression of Rb plus p300. Our ®ndings suggest that: (1) disruption of the LXCXE motif within the N-terminal RB binding region alters the biologic function of BRCA1; and (2) over-expression of BRCA1 inhibits the expression of RB and RB family (p107 and p130) proteins. Oncogene (2001) 20, 4827 ± 4841.
Introduction
BRCA1 gene mutations confer an increased risk for breast, ovarian, and prostatic cancers (Miki et al., 1994; Ford et al., 1994; Streuwing et al., 1997) . The BRCA1 gene encodes an 1863 amino acid (aa), 220 kDa nuclear protein with an N-terminal RING domain that interacts with various cell cycle regulatory proteins (Wang et al., 1997 ) and a C-terminal transcriptional activation domain (TAD) (Monteiro et al., 1996) (see Figure 1 ). Over-expression of BRCA1 inhibits cell growth and renders cells more susceptible to apoptosis (Holt et al., 1996; Shao et al., 1996; Fan et al., 1998) ; while decreased BRCA1 expression stimulates proliferation and is found in sporadic breast cancers (Thompson et al., 1995) . BRCA1 participates in the regulation of cell cycle, apoptosis, and DNA repair pathways (Shao et al., 1996; Fan et al., 1998; Thompson et al., 1995; Somasundaram et al., 1997; Scully et al., 1997; Gowen et al., 1998) . Breast cancers from patients with BRCA1 mutations have 2 ± 3-fold more chromosomal aberrations than sporadic cancers (Tirkkonen et al., 1997) , suggesting a role for BRCA1 as a`caretaker' gene in ensuring the maintenance of genomic integrity. We showed that BRCA1 inhibits the transcriptional activity of the estrogen receptor (ER-a), suggesting a potential role in breast cancer suppression by regulating estrogen-stimulated mammary cell growth (Fan et al., 1999) .
Recent studies suggest that some of these BRCA1 functions may be mediated by functional interactions with two other tumor suppressor proteins: p53 and the retinoblastoma protein (RB). BRCA1 binds to p53 via two sites, one in the C-terminal minimal TAD (aa 1760 ± 1863) and the other located Nterminally (aa 224 ± 500) (Zhang et al., 1998; Ouichi et al., 1998; Chai et al., 1999) . The BRCA1:p53 interaction results in increased sequence-speci®c transcriptional activity of p53, suggesting that BRCA1 may function as a co-activator for p53. The C-terminus of BRCA1 also interacts with RB, two RB-associated proteins (RbAp46 and RbAp48), and histone deacetylases (HDAC-1 and HDAC-2) (Yarden and Brody, 1999) .
A second, more N-terminal RB-binding on BRCA1 was also identi®ed (aa 304 ± 394) (Aprelikova et al., 1999) . Furthermore, the ability of BRCA1 to induce cell cycle arrest at the G1/S border was signi®cantly reduced in Rb (7/7) mouse embryo ®broblasts, as compared with the corresponding Rb (+/+) and Rb (+/7) cells (Aprelikova et al., 1999) . These ®ndings suggest that some of the functional activities of BRCA1 may be mediated through a BRCA1:RB protein interaction. The N-terminal RB binding region of BRCA1 contains a consensus RB family protein binding motif, LXCXE (aa 358 ± 362). However, the role of this 358 LXCXE motif of BRCA1 in mediating the BRCA1:RB physical interaction or its functional consequences is not known.
In this report, we demonstrate that the LXCXE motif embedded inside the N-terminal RB-binding region of BRCA1 is not necessary for binding of BRCA1 to RB, nor is an intact A/B binding pocket of RB required for binding. However, this motif is required for the functional consequences of the BRCA1:RB interaction, including the down-regulation of RB and the RB-related proteins (p107 and p130) and the induction of cellular chemosensitivity to DNAdamaging agents.
Results

BRCA1:RB protein interaction does not require LXCXE (aa 358 ± 362)
We used the GST capture assay (Wang et al., 1993) to investigate the physical interaction between the BRCA1 and RB. The BRCA1 cDNAs tested in this study are illustrated in Figure 1 ; and the ability of a GST-RB fusion protein containing the ABC domains of the wild-type RB protein (see Figure 2a ) to pull down dierent BRCA1 proteins is shown in Figure 2b . GST-RB captured wtBRCA1 (aa 1 ± 1863), D BamH1 (aa 1 ± 1313), and D KpnI (aa 1 ± 771) but did not capture D EcoRI (aa 1 ± 302). As a negative control, GST alone failed to capture any BRCA1 proteins. Further studies revealed that BRCA1 D KpnI and D BamHI were pulled down by two GST-RB mutants defective in the A/B binding pocket: RB D Exon 21 and RB D Exon 22 (Figure 2c ). However, D EcoRI (1 ± 302) was not captured by any of these RB proteins. The RB D Exon 21 mutation corresponds to the RB mutation found in DU-145 cells (Sarkar et al., 1992) .
Both wtBRCA1 and a full-length BRCA1 with the mutation 358 LXCXE? 358 RXRXH were captured by GST-RB, RB D Exon 21, and RB D Exon 22 ( Figure  2d ). Somewhat surprisingly, two truncated forms of BRCA1, D KpnI (1 ± 771) and D MscI (aa 1 ± 440) with the mutation LXCXE?RXRXH were pulled down by each RB protein (Figure 2d ). These ®ndings suggest that there is an RB-binding site within aa 303 ± 440 of BRCA1, but that neither the LXCXE site of BRCA1 (aa 358 ± 362) nor an intact A/B binding pocket of RB is essential for the BRCA1:RB physical interaction. As was observed for RB, the full-length wtBRCA1 protein was pulled down by GST fusion proteins containing the ABC domains of p107 and p130, but not by GST alone (Figure 2e ). Consistent with the ®ndings for RB, GST-p107 and GST-p130 also captured the full-length BRCA1 protein containing the mutation LXCXE?RXRXH as well as a truncated BRCA1 protein containing only aa 1 ± 771 (BRCA1 D KpnI). However, in side-by-side comparisons, it appears that pull-down of BRCA1 by GST-p107 or GST-p130 was less than that of GST-RB. These ®ndings suggest that p107 and p130 can also interact with the N-terminal region of BRCA1, and the LXCXE motif of BRCA1 is not required for the interaction of BRCA1 with p107 or p130.
BRCA1:RB interaction and co-localization in vivo
Consistent with previous reports (Yarden and Brody, 1999; Aprelikova et al., 1999) , we detected an in vivo interaction of BRCA1 and RB by IP (immunoprecipitation)-Western blotting. RB was detected in BRCA1 IPs of DU-145 prostate cancer cells and MCF-7 breast cancer cells; while control IPs with non-immune IgG or an irrelevant monoclonal yielded no RB band (illustrated in Figure 3a) . BRCA1 was detected in RB IPs in some but not all experiments (data not shown). The inability to consistently detect BRCA1 in RB IPs may be a technical problem related to disruption of the BRCA1:RB complex by the RB antibodies (C-15-G or IF8), since these antibodies eectively precipitated RB and since the in vivo BRCA1:RB interaction is welldocumented by others (Yarden and Brody, 1999; Aprelikova et al., 1999) .
Since the RB gene in DU-145 cells has an in-frame deletion of exon 21 (corresponding to RB D Exon 21 in the GST capture assays), an intact A/B binding pocket does not appear to be necessary for the BRCA1:RB interaction in vitro or in vivo. Next, we performed IPWestern blots of DU-145 cells stably transfected with wtBRCA1 or BRCA1-RXRXH. Consistent with the in vitro binding assays, RB was detected in the BRCA1 IP of BRCA1-RXRXH clones. But surprisingly, there was little or no RB in the BRCA1 IP of the DU-145 wtBRCA1 clone ( Figure 3b) ; and a similar result was obtained using wtBRCA1 and BRCA1-RXRXH clones of MCF-7 cells, which have wild-type RB (see Figure  3c ). As will be demonstrated later, the failure to IP signi®cant quantities of RB protein along with BRCA1 in wtBRCA1-transfected cell clones is probably due to the down-regulation of RB induced by over-expression of wtBRCA1.
Consistent with a prior study (Aprelikova et al., 1999) , it was primarily the hypophosphorylated form of RB (lower M r ) that associated with BRCA1 (compare RB in MCF-7 lysates vs that in BRCA1 IPs in Figure 3a ,b,c. The BRCA1:RB association was also demonstrated in other untransfected human breast cancer (T47D, MDA-MB-231, MDA-MB-453) and untransfected human prostate cancer (TsuPr-1, LnCAP) cell lines (data not shown).
Finally, we examined the in vivo association of endogenous BRCA1 and RB in subcon¯uent proliferating MCF-7 cells by confocal laser scanning microscopy. Both proteins showed a predominantly nuclear distribution, although some of the BRCA1 was also observed in the cytoplasm (Figure 4a ). There was some variability in the levels of BRCA1 from cell to cell, consistent with its known cell cycle dependent pattern of expression (Chen et al., 1996; Rajan et al., 1996) . In the merged images, there was signi®cant co-localization (bright yellow color) in nuclear granules of cells containing nuclear BRCA1; but there was no colocalization of cytoplasmic BRCA1 with RB. In this study, neither BRCA1, nor RB, showed any signi®cant nucleolar localization.
As a control, BRCA1 failed to co-localize with the glucocorticoid receptor (GR), which shows a characteristic distribution at the periphery of the nucleus (Figure 4b ). The light green and orange-red coloration probably represents some overlapping of the distributions of BRCA1 and GR, but there is no obvious colocalization, which would appear as bright yellow. Both the GR and merged images show some nucleolar distribution of GR. Note that in the photograph shown, the green color of the BRCA1 panels reproduced slightly darker than it actually was: the actual shade of green was closer to the light green of the merged image, again suggesting little or no colocalization.
BRCA1 down-regulates the expression of RB and RB-related proteins
To facilitate studies of BRCA1 functional activity in DU-145 cells, we developed cell lines expressing the wtBRCA1 gene under the control of a tetracycline (TCN)-regulated promoter system. Cells were subjected to two transfections using the Tet-O system (Clonetech): (1) plasmid pTet-O; and (2) plasmid pTREwtBRCA1 (containing the Tet operator and wtBRCA1 cDNA). Clones were screened for BRCA1 expression when TCN (2 mg/ml) was removed from the medium.
The BRCA1 mRNA and protein levels were increased at 24 h or more after the removal of TCN from DU-145/Tet-O/BRCA1 clones, but not from control (DU-145/Tet-O/Neo) cell clones (Figure 5a ). Removal of TCN from the medium caused a quantitative reduction in RB mRNA and protein levels at 24, 48 and 72 h in DU-145/Tet-O/BRCA1 cells (see Figure 5b ,c).
In parallel to the reduction in RB, the levels of the RB-related proteins p107 and p130 were also signi®-cantly decreased at 24 ± 72 h after removal of TCN from the culture medium ( Figure 5c ). Similarly, stably transfected wtBRCA1 clones of DU-145 cells exhibited reduced levels of RB, p107, and p130, as compared with control (neo) cell clones (Figure 5d ). Treatment of the wtBRCA1 stable DU-145 clone with inhibitors of proteasomal degradation (MG-132), caspase-3, or caspase-6 caused little or no change in the levels of RB, p107, or p130 (Figure 5d ). Finally, MCF-7 cell clones transfected with the wtBRCA1 cDNA also showed reduced levels of the RB, p107, and p130 proteins, as compared with control (neo) cell clones (illustrated in Figure 5e ).
BRCA1-RXRXH fails to down-regulate RB and reverses wtBRCA1-mediated down-regulation
We utilized a DU-145/Tet-O/BRCA1 cell line to determine the eects the BRCA1-RXRXH transgene on the expression of RB and the RB-related proteins. Cells were transfected overnight with BRCA1-RXRXH and incubated in the presence (+) or absence (7) of TCN for dierent times before harvesting for Western blot analysis. As expected, the removal of TCN from the medium caused down-regulation of RB, p107, and p130 protein levels, as compared with cells incubated +TCN ( Figure 6 ). Cells transfected with BRCA1-RXRXH and incubated +TCN failed to exhibit a decrease in the protein levels of RB, p107, or p130, suggesting that the mutation LXCXE?RXRXH abrogates the ability of BRCA1 to down-regulate RB family genes.
Furthermore, cells transfected with BRCA1-RXRXH and incubated 7TCN also failed to downregulate RB and only partially down-regulated the p107 and p130 proteins, suggesting that when wtBRCA1 and BRCA1-RXRXH are co-expressed, BRCA1-RXRXH fully or partially blocks the ability of wtBRCA1 to induce the down-regulation of RB 
BRCA1-RXRXH confers a phenotype opposite to wtBRCA1 in DU-145 cells
To determine if inactivation of the LXCXE site alters the functional activity of the BRCA1 protein, we compared the phenotype of stably transfected BRCA1-RXRXH vs wtBRCA1 (positive control for BRCA1 function) vs empty vector (neo) (negative control) DU-145 cell clones. The total BRCA1 mRNA and protein levels were similar in RXRXH vs wtBRCA1 clones; and both clonal types had higher BRCA1 mRNA and protein levels than the control (neo and parental) cells ( Figure 7a ). Major dierences were observed in the chemosensitivity of these clonal types. Thus, wtBRCA1 cell clones were more sensitive than neo to the DNA topoisomerase IIa inhibitor adriamycin (ADR) and to the topoisomerase I inhibitor camptothecin (CPT). However, BRCA1-RXRXH cell clones were more resistant to ADR than the neo clones ( Figure 7b ). Agarose gel electrophoresis revealed that the BRCA1-RXRXH clones were more resistant and the wtBRCA1 clones were more sensitive than control (neo) cells to ADRor CPT-induced apoptosis ( Figure 7c ). Similar results were obtained using MCF-7 cell clones (Figure 7d ), demonstrating that the BRCA1-RXRXH gene also Figure 4 Co-localization of endogenous BRCA1 and RB in the nuclei of MCF-7 human breast cancer cells. In confocal immuno¯uorescence studies of asynchronously proliferating MCF-7 cells, BRCA1 showed a nuclear plus cytoplasmic distribution, while RB showed a predominantly nuclear, but extra nucleolar, distribution (a). In the merged images, there is signi®cant colocalization (yellow color) within nuclear granules of cells containing nuclear BRCA1. On the other hand, there is no co-localization of cytoplasmic BRCA1 and RB. As a negative control, BRCA1 failed to localize with the glucocorticoid receptor (GR), which shows a characteristic localization at the periphery of the nucleus (b) induces chemoresistance in a breast cancer cell line with wild-type RB.
There were only minor dierences in the in vitro growth kinetics of the dierent DU-145 clonal types. The population doubling times (T d ) were: 20 h (BRCA1-RXRXH), 25 h (wtBRCA1), and 22 h (neo) (see Figure 8a ). And¯ow cytometric analysis of the cell cycle revealed no evidence of cell cycle block or arrest in the wtBRCA1 cell clones (Figure 8b ). In fact, the only apparent dierence in the cell cycle distributions of neo, wtBRCA1, and RXRXH clones was that the RXRXH clones had a slightly smaller percentage of cells in G1 and a slightly larger percentage in S phase.
To determine if the LXCXE?RXRXH mutation in¯uences in vivo tumor growth, we compared the growth of DU-145 cell clones as tumors in the subcutaneous tissue of male nude mice. The wtBRCA1 clonal tumors showed a signi®cantly decreased growth rate as compared with control (neo) clones (P50.001) (Figure 8c ). In contrast, the BRCA1-RXRXH clonal tumors continued to grow rapidly, and their growth pattern was indistinguishable from that of the control (neo) tumors (P40.1).
RXRXH phenotype demonstrated by transient transfection assays
We observed the RXRXH-mediated chemoresistance as well as RXRXH-mediated reversal of wtBRCA1-induced chemosensitivity in transient transfection assays using a DU-145/Tet-O/BRCA1 clone ( Figure  9 ). In these experiments, transient transfection of BRCA1-RXRXH caused a decrease in sensitivity to ADR in cells expressing baseline endogenous levels of BRCA1 (+TCN conditions); and BRCA1-RXRXH overcame the chemosensitization induced by wtBRCA1 expression following the removal of TCN (7TCN conditions). These results parallel the studies of RB family protein regulation, in which BRCA1-RXRXH failed to down-regulate these proteins and inhibited the ability of wtBRCA1 to cause down-regulation of the protein levels. wtBRCA1 cell clones also exhibit reduced RB family (RB, p107, and p130) protein levels, as compared with control (neo) cell clones; and the levels of these proteins were not restored by treatment for 24 h with inhibitors of the proteasomal degradation pathway (MG-132, 10 mM), caspase-3 (Casp-3 I, 25 mM), or caspase-6 (Casp-6 I, 25 mM). (e) MCF-7 breast cancer cells stably expressing wtBRCA1 show decreased RB family protein levels, as compared with control (neo) cells
Regulatory protein expression in DU-145 BRCA1-RXRXH vs wtBRCA1 cell clones
We reported that DU-145 cell clones stably transfected with wtBRCA1 showed a set of alterations in the levels of various cellular regulatory proteins, as compared with control (parental and neo-transfected) cells: : BRCA2, ; p300, ; Mdm-2, ; p21 Waf1/Cip1 , ; Bcl-2, and ; Bax (Fan et al., 1998) . A variety of other cellular proteins were not altered by wtBRCA1 [e.g., Bcl-X L , PCNA (proliferating cell nuclear antigen), CBP (CREB-binding protein), a-actin]. To determine if BRCA1-RXRXH induces alterations in these proteins, we compared the protein levels in three BRCA1-RXRXH clones vs three control (neo) clones (negative control), and one wtBRCA1 clone (positive control).
Figure 6 BRCA1-RXRXH blocks the down-regulation of RB expression mediated by wtBRCA1. Subcon¯uent proliferating DU-145/Tet-O/BRCA1 cells were transfected overnight+BR-CA1-RXRXH (15 mg plasmid DNA per 100 mm dish) and then incubated in the presence (+) or absence (7) of TCN (2 mg/ml) for the indicated times. Cells were then harvested and subjected to Western blot analysis (50 mg cell protein per lane) to detect the RB, p107, p130, and a-actin (control) proteins Western blots and densitometry analyses of protein levels are shown in Figure 10a ,b, respectively. As expected, based on our previous study, the wtBRCA1 clone showed increased levels of BRCA1 and BRCA2 and decreased levels of p300, Mdm-2, p21
Waf1/Cip1 , Bcl-2, and Bax. The BRCA1-RXRXH clones showed increased levels of BRCA1 protein, consistent with the expression of the BRCA1-RXRXH protein. However, the levels of BRCA2 in BRCA1-RXRXH clones were not markedly increased, and the levels of the other proteins were not signi®cantly decreased, relative to neo clones. In fact, the levels of Mdm-2, which induces cell cycle progression and inhibits p53, were 2.6-fold higher in BRCA1-RXRXH clones than in neo clones. Thus, the LXCXE?RXRXH mutation abrogates the ability of BRCA1 to induce alterations in regulatory protein levels.
Reversal of wtBRCA1-mediated chemosensitivity by co-expression of RB and p300 cDNAs
In the studies described above, the wtBRCA1-induced down-regulation of RB family and other regulatory proteins appeared to correlate with an increased sensitivity to the DNA-damaging agent ADR. We used the TCN-regulated wtBRCA1 expression system in DU-145 cells to determine if co-expression of RB family genes along with wtBRCA1 could block the BRCA1-induced chemosensitivity. DU-145/Tet-O/ BRCA1 cells were transiently transfected with expression vectors for RB, p107, p130, or empty pcDNA3 vector and then tested for ADR-induced cytotoxicity, in the presence (+) or absence (7) of TCN. The results are shown in Figure 11 .
In the +TCN cells, exposure to ADR (15 mM62 h) resulted in 70 ± 75% cell viability after 48 h, in The percentages of cells in the G1, S, and G2-M phases are means+s.e.m. for three dierent clones of each clonal type. Subcutaneous tumor growth rates of wtBRCA1 vs BRCA1-RXRXH vs control (neo) clones were determined as described in the Materials and methods section (c). For almost all time points, the wtBRCA1 tumors grew signi®cantly more slowly than the neo tumors (P50.001. two-tailed t-test); while the growth rate of BRCA1-RXRXH tumors was similar to that of neo tumors (P40.1) Figure 9 Transient RXRXH expression causes chemoresistance and reverses wtBRCA1-mediated chemosensitivity. Transient transfection of BRCA1-RXRXH but not pcDNA3 vector conferred increased survival after exposure to ADR in cells with baseline BRCA1 levels (+TCN). Over-expression of wtBRCA1 in the same cells (7TCN) conferred increased sensitivity to ADR. The wtBRCA1-induced sensitization to ADR was reversed by transfection of BRCA1-RXRXH but not empty pcDNA3 vector. Comparisons of cell viability of BRCA1-RXRXH transfected cells vs control (untransfected or pcDNA3 vector-transfected) cells yielded P50.001 for both +TCN and 7TCN conditions. Methodology. DU-145/Tet-O/BRCA1 cells were transfected overnight with BRCA1-RXRXH, pcDNA3 vector, or vehicle only (15 mg per 100 mm dish). Cells were washed and incubated in fresh medium for 3 h. They were then harvested with trypsin, counted, seeded into 96-well dishes (3000 cells/well) without or with TCN (2 mg/ml), and allowed to attach and recover for 24 h. Cells were incubated with ADR (15 mM62 h), washed, postincubated in drug-free medium for 48 h, and assayed for MTT dye conversion. Cell viability is expressed relative to controls; and the values are means+s.e.m. of 10 replicate wells untransfected or empty vector transfected control cells. The expression of BRCA1 by removal of TCN (7TCN) caused a reduction of cell viability to 17 ± 20% in the control or vector transfected cells. However, transfection of each of the three Rb family genes or all three genes together caused modest but signi®cant increases in cell viability in the 7TCN cells, to the range of 29 ± 41%. Transfection of the p300 expression vector caused an even larger increase in cell viability, to about 60%; while the co-transfection of RB plus p300 restored the survival of ADR-treated cells to over 90%, even under 7TCN conditions. Thus, it appears that in the presence of ectopically expressed Rb+p300, wtBRCA1 expression no longer induces chemosensitivity to ADR in DU-145 cells.
Discussion
We showed that BRCA1 can bind to the RB protein through an N-terminal binding site located between aa 302 and 440. This ®nding is consistent with a previous report demonstrating an RB-binding site between aa 304 and 394 (Aprelikova et al., 1999) . We further showed that the consensus RB-binding motif LXCXE (aa 358 ± 362) is not required for the BRCA1:RB interaction in vitro or in vivo. Thus, the mutation LXCXE?RXRXH did not abrogate the binding of RB to BRCA1, although our studies do not indicate whether this mutation alters the quantitative binding anity. Mutations that disrupt the con®guration of the A/B binding pocket of RB (RB D Exon 21 and D Exon 22) ± the domain that contacts the LXCXE sites of various RB-binding proteins (Zalvide and DeCaprio, 1995; Lee et al., 1998) ± did not abrogate the BRCA1:RB interaction. These ®ndings suggest that the BRCA1:RB interaction does not involve a typical LXCXE:pocket domain interaction.
Although not all LXCXE-containing proteins interact with RB, the fact that the BRCA1 LXCXE (aa 358 ± 362) is embedded in an RB-binding region suggests that it may play a functional role, even though it is not required for the binding. A clue to this role is the ®nding that ectopic expression of a wtBRCA1 gene caused down-regulation of RB, p107, and p130 expression; while a full-length BRCA1 gene with the mutation LXCXE?RXRXH did not aect RB family expression. Along with down-regulation of RB family proteins, cells expressing wtBRCA1 were more sensitive to cytotoxicity and apoptosis induced by the DNA-damaging agents ADR and CPT; while cells expressing BRCA1-RXRXH were less sensitive to these agents. Similarly, wtBRCA1 enhanced and BRCA1-RXRXH reduced the cellular sensitivity to ionizing radiation (unpublished data). Table 1 compares the amino acid sequences surrounding the LXCXE motif of human BRCA1 with those from the corresponding regions of BRCA1 from other species. This analysis revealed the LXCXE motif was conserved among higher primates but was not conserved or only partially conserved in most lower species. However, there was a signi®cant degree of conservation of the sequences immediately preceding and following the LXCXE motif, and there was virtual identity within an 18 amino acid region starting at the seventh amino acid after the LXCXE (boxed region in Table 1 ). These considerations suggest two possibilities: (1) the LXCXE of BRCA1 serves a function unique to humans and higher primates, which is disrupted by the RXRXH mutation; or (2) the RXRXH mutation induces a conformational alteration which disrupts an evolutionarily conserved biologic function mediated by amino acid sequences near the LXCXE motif.
If the hypothesis that BRCA1 regulates the expression of the RB protein is correct, then gene mutations that disrupt the ability of BRCA1 to regulate RB could also disrupt the ability of BRCA1 to regulate the cell cycle and to mediate tumor suppression. This idea is consistent with the ®nding of reduced ability of wildtype BRCA1 to cause a G1/S cell cycle block in Rb (7/7) mouse embryo ®broblasts (MEFs), as compared with Rb (+/7) and Rb (+/+) cells (Aprelikova et al., 1999) . It is also interesting to note that Brca1 (7/7) MEFs show a severe de®cit in cell proliferation Figure 11 Reversal of BRCA1-mediated chemosensitivity by the co-expression of RB and p300. Transient expression of RB, p107, p130, or all three genes partially blocked the increased chemosensitivity to adriamycin (ADR) caused by the expression of wtBRCA1 following the removal of tetracycline (TCN) from the culture medium of subcon¯uent proliferating DU-145/Tet-O/ BRCA1 cells. Expression of a wild-type p300 gene partially but strongly blocked the chemosensitivity. However, co-expression of p300 plus RB restored the BRCA1-induced chemosensitivity essentially to the control (+TCN) levels. Methodology. Subconuent proliferating DU-145/Tet-O/BRCA1 cells were transfected overnight with the indicated vector(s) (10 mg of plasmid DNA per 100 mm dish), washed, and allowed to recover by incubation in fresh culture medium for 3 h. The cells were then harvested with trypsin, counted, seeded into 96-well dishes (3000 cells/well) without (7) or with (+) TCN, and allowed to attach and recover for 24 h. Cells were incubated with ADR (15 mM62 h), washed, post-incubated in drug-free culture medium for 48 h, and assayed for MTT dye conversion. Cell viability is expressed relative to non-ADR treated control cells. Cell viability values are the means+s.e.m. of 10 replicate wells Table 1 Comparison of BRCA1 amino acid sequences in dierent species BRCA1 regulation of RB family S Fan et al (Hakem et al., 1996) , while no such defect is exhibited in Rb (7/7) MEFs. If the above hypothesis is correct, Brca1 (7/7) cells should have very high levels of Rb, consistent with growth suppression. Our ®ndings suggest that the LXCXE motif in the N-terminal RB-binding domain of BRCA1 participates in the regulation of RB family protein expression as well as the regulation of cellular chemosensitivity and apoptosis. Since a variety of studies have implicated RB in the regulation of apoptosis (Doostzadeh-Cizeron et al., 1999; Samuelson and Lowe, 1997; Lin et al., 1996) , the ability of BRCA1 to induce chemosensitivity and increased susceptibility to apoptosis (Shao et al., 1996; Fan et al., 1998; Harkin et al., 1999) may be due, in part, to its ability to down-regulate RB expression through a mechanism that requires the LXCXE motif. One mechanism by which RB regulates apoptosis is by inhibition of apoptosis caused by the cell cycleregulated transcription factor E2F-1 (Tsai et al., 1998; Field et al., 1996; Hsieh et al., 1997) . E2F-1 causes apoptosis by a mechanism dependent upon its DNA-binding domain but not its transcriptional activation domain (TAD); and over-expression of RB blocked the E2F-1 induced apoptosis (Hsieh et al., 1997) . Although the TAD of E2F-1 was not required for apoptosis induction, the RB-binding domain, which is located within the TAD, was required for the inhibition of E2F-1 mediated apoptosis by RB (Hsieh et al., 1997) .
The mechanism of E2F-1 induced apoptosis is not entirely clear, but the study cited above suggests that relief of active repression of genes targeted by the E2F-1 transcription factor may be involved. The binding of RB to the E2F-1 TAD and the recruitment of histone deacetylases (HDACs) by the A/B binding pocket of RB provides a mechanism for active repression of genes containing E2F-1 binding sites (Brehm et al., 1998; Magnaghi-Jaulin et al., 1998) . Presumably, the DNA-binding domain of E2F-1 is sucient to induce apoptosis by displacing E2F-1:RB:HDAC repression complexes from the E2F-1 sites of target genes, thus stimulating transcription from these genes (Hsieh et al., 1997) . One of these E2F-1 target genes is INK4a/ p14 ARF (Quelle et al., 1995) . The p14 ARF protein and its murine homolog p19 ARF interact with Mdm-2 and block Mdm-2 mediated degradation of p53, thus resulting in stabilization of p53 (Pomerantz et al., 1998; Tao and Levine, 1999) . In fact, it was recently demonstrated that BRCA1, which functions as a coactivator for p53 (Zhang et al., 1998; Ouichi et al., 1998; Chai et al., 1999) , can stabilize the p53 protein through a mechanism that requires p14 ARF (Somasundaram et al., 1999) .
The above mechanism might explain the ability of the wtBRCA1 gene to induce chemosensitivity in cells with wild-type RB and p53 (e.g., MCF-7). However, it does not explain the BRCA1-induced chemosensitivity of DU-145 cells (Fan et al., 1998 and this study) , since these cells have mutations of both Rb (an in-frame deletion of exon 21) and p53 (a double point mutation of the sequence-speci®c DNA-binding domain) (Sarkar et al., 1992; Carroll et al., 1993) . Thus, if the A/B pocket-defective mutant RB of DU-145 cells is unable to inhibit E2F-1, the down-regulation of RB induced by wtBRCA1 would not be expected to cause chemosensitivity.
Several explanations might account for the ability of wtBRCA1 to enhance chemosensitivity and apoptosis susceptibility in DU-145 cells: (1) the pocket-defective mutant RB in these cells can modulate chemosensitivity by a mechanism independent of E2F-1; (2) one of the RB-related proteins, p107 or p130, both of which are expressed in DU-145 cells, can substitute for RB; and (3) wtBRCA1-mediated chemosensitivity could be due, in part, to mechanisms independent of the RB family. The ability of BRCA1 to induce down-regulation of p107 and p130 in DU-145 cells is consistent with the second explanation, as is the observation that BRCA1 can also interact with p107 and p130.
The mechanism by which wtBRCA1 (but not BRCA1-RXRXH) down-regulates RB and RB-related proteins is not clear at this time. However, wtBRCA1 expression caused a signi®cant reduction of RB mRNA as well as protein levels; and the protein levels were not restored by treatment with inhibitors of the ubiquitinproteasome pathway or with inhibitors of caspases-3 and -6. These ®ndings suggest that the BRCA1 regulation of RB occurs primarily at the mRNA level and raise the possibility that the RB gene may be a target for transcriptional repression by BRCA1.
Recent studies suggest a role for BRCA1 in transcriptional repression. Thus, BRCA1 inhibits the transcriptional activity of the estrogen receptor (Fan et al., 1999) . And the C-terminal region of BRCA1 found interacts with transcriptional co-repressors, such as HDACs and the C-terminal interacting protein (CtIP), which recruits the co-repressor CtBP (C-terminal binding protein) (Yarden and Brody, 1999; Yu et al., 1998) . These ®ndings are consistent with the observation that BRCA1 down-regulates other gene products at the mRNA level, such as the transcriptional coactivator p300 (Fan et al., 1998) . The ability of wtBRCA1 to inhibit p300 expression was also abrogated by the LXCXE?RXRXH mutation.
The chemosensitivity induced by expression of wtBRCA1 was partially dependent upon both RB and p300, since co-expression of RB plus p300 blocked wtBRCA1-mediated chemosensitivity. Like RB, BRCA1 was found to interact directly with CBP/p300 (Pao et al., 2000) . Binding of CBP was mediated by BRCA1 fragments containing aa 1 ± 303 and aa 1314 ± 1863, but not by a fragment containing the N-terminal RB protein binding site (aa 303 ± 772). However, the role of the BRCA:CBP/p300 interaction in modulating chemosensitivity remains to be determined.
Interestingly, the expression of BRCA1-RXRXH not only abrogated the ability of BRCA1 to induce chemosensitivity, but also conferred chemoresistance and resistance to apoptosis induction in several dierent cell types. While the failure of BRCA1-RXRXH to induce down-regulation of RB and RBrelated proteins could explain a failure to induce chemosensitivity, it would not explain why cell lines that express the BRCA1-RXRXH protein are actually more chemoresistant than control (parental or vectortransfected) cell lines. The chemoresistance of these cells might be explained by inhibition of the endogenous wild-type BRCA1 by BRCA1-RXRXH. The latter possibility is suggested by the ®nding that transient expression of a BRCA1-RXRXH genes blocks the chemosensitization of DU-145/Tet-O/BRCA1 cells induced by removal of TCN from the medium.
The ability of BRCA1-RXRXH to block the chemosensitization of DU-145 cells induced by the over-expression of wtBRCA1 correlated with its ability to block the wtBRCA1-mediated down-regulation of RB and the RB-related proteins (p107 and p130) in the same cell line under the same conditions. The BRCA1-RXRXH protein might act to sequester other BRCA1-interacting proteins, thus disrupting speci®c protein ± protein interactions required for the BRCA1-mediated down-regulation of the RB gene family and the BRCA1-mediated chemosensitivity.
In conclusion, we found that the LXCXE motif within the N-terminal RB-binding domain of BRCA1 is not necessary for the physical interaction of BRCA1 and RB but is required for two potential functional consequences of that interaction: (1) the downregulation of expression of RB family proteins; and (2) the BRCA1-induced chemosensitivity and susceptibility to apoptosis induction by DNA-damaging agents. Thus, the 358 LXCXE motif of BRCA1 is a functionally important site in mediating some of the tumor suppressor functions of BRCA1 and RB.
Materials and methods
BRCA1 and RB family expression vectors BRCA1
The wild-type BRCA1 expression plasmid (wtBRCA1) was created by cloning the BRCA1 cDNA into the mammalian expression vector pcDNA3 (Invitrogen Corporation, Carlsbad, CA, USA) using arti®cially engineered 5' HindIII and 3' NotI sites. Mutant BRCA1 and truncated BRCA1 expression vectors were created by modi®cation of the wtBRCA1 cDNA in the pcDNA3 vector (see Figure 1) . The BRCA1 cDNAs utilized in this study are illustrated schematically in Figure 1 .
RB family
The following expression vectors were used to express RB family proteins: pSG5-Rb, pCMV-p107, and pcDNA3-p130 (provided by Dr Richard Pestell, Department of Medicine and Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, New York, USA) (Pestell et al., 1996) . The p300 expression vector (pcDNA3-p300) was also provided by Dr Richard Pestell.
GST-RB vectors for GST capture assays
The following vectors were utilized to express the ABC domains of GST-RB fusion proteins: pGEX2T-Rb (aa 379 ± 928), pGEX2T-Rb 379 ± 928 D exon 21 (missing aa 703 ± 737), and pGEX2T-Rb 379 ± 928 D exon 22 (missing aa 738 ± 775) (Kaelin et al., 1991) . These three vectors were provided by Dr WG Kaelin, Jr. (Dana-Farber Cancer Institute, Boston, MA, USA). The vectors pGEX2T-p107 (aa 252 ± 936) (Cress et al., 1993) and pGEX3X-p130 (aa 322 ± 1139) (23), which were utilized to express GST fusion proteins of the ABC domains of RB family proteins p107 and p130, respectively, were provided by Dr Douglas Cress (H Lee Mott Cancer Center and Research Institute, University of South Florida, USA).
Sources of reagents
The DNA-damaging agents adriamycin (ADR) (doxorubicin hydrochloride) and camptothecin (CPT) were purchased from the Sigma Chemical Company (St. Louis, MO, USA). The primary antibodies used for Western blotting and their sources are described below under Western blotting. MTT dye [3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide] was also obtained from Sigma. G418 (geneticin) was obtained from Boehringer Mannheim. The cell permeable inhibitors of protein degradation used in this study were as follows: proteasomal degradation inhibitor (MG-132), caspase-3 inhibitor I, and caspase-6 inhibitor II. Each inhibitor was obtained from the Calbiochem-Novabiochem Corporation (La Jolla, CA, USA).
Tetracycline (TCN)-regulated BRCA1 expression system
The TCN-regulated expression system was created using the pTet-O system (Clonetech Laboratories, Inc., Palo Alto, CA, USA) (Freundlieb et al., 1997) . This system has two major components: (1) the regulator plasmid pTet-O, which expresses a fusion of the Tet repressor (TetR) and VP16 activation domain of herpes simplex virus under control of the strong immediate early CMV promoter; and (2) the response plasmid pTRE, which contains the Tet-responsive element (TRE) (seven copies of 42 bp Tet operator) upstream of the minimal immediate early CMV promoter and a multicloning site (MCS).
DU-145 human prostate cancer cell clones were established by two separate stable transfections, the ®rst with pTet-O and the second with pTRE containing the full-length wtBRCA1 cDNA cloned into the MCS (pTRE-wtBRCA1). Double stable Tet-O cell clones (designated DU-145/Tet-O/BRCA1) were screened and chosen for BRCA1 expression induced by removal of TCN, by semi-quantitative RT ± PCR analysis and by Western blotting (see below).
Cell lines, cell culture, and transfection DU-145 human prostate cancer cells, MCF-7 human breast cancer cells, and other human cancer cell lines were originally obtained from the American Type Culture Collection (Rockville, MD, USA). Cells were grown in Dulbecco's Modi®ed Eagle's Medium (DMEM) supplemented with 5% v/v (DU-145) or 10% v/v (MCF-7) fetal calf serum, L-glutamine (5 mM), non-essential amino acids (5 mM), penicillin (100 U/ ml), and streptomycin (100 mg/ml) (all obtained from BioWhittaker (Walkersville, MD, USA) (Fan et al., 1998) . Cell lines were incubated in a humidi®ed atmosphere of 95% air and 5% CO 2 and were subcultured weekly, using trypsin.
For stable transfections, cells in 100 mm plastic Petri dishes at about 30 ± 40% of con¯uence were incubated overnight with 5 mg of plasmid DNA, using Lipofectin (GIBCO Life Technologies, Rockville, MD, USA), according to the manufacturer's instructions. Cells were then selected in G418 (0.5 mg/ml). The G418-resistant colonies were isolated using cloning rings, expanded, and screened for BRCA1 expression by Western blot and RT ± PCR assays. Clones that stably over-expressed BRCA1 were frozen in liquid nitrogen.
For transient transfection assays, subcon¯uent proliferating cells were incubated overnight with 10 mg of plasmid DNA per 100 mm dish, in the presence of Lipofectin, and then washed to remove the Lipofectin and the excess plasmid DNA.
Semi-quantitative reverse transcriptase-polymerase chain reaction (RT ± PCR) analysis
The mRNA expression of the wild-type and mutant BRCA1 transgenes was veri®ed by semi-quantitative RT ± PCR assays, as described before by us (Fan et al., 1998) . The BRCA1 primer sequences (5'?3') and the locations within the cDNA sequence [GenBank accession number U15595 (1)] were as follows: sense TTG CGG GAG GAA AAT GGG TAG TTA; and antisense GAA GTA GTA AGT GGG AAC CGT GT (bp 5239 to 5523, 285-bp product). The Rb primer sequences (5'?3') were as follows: sense TGC ACG AGT TGA CCT AGA TGA G; and antisense TCT TTG AGC AAC ATG GGA GG (bp 453 to 849, 397-bp product). The primers for the control gene, û-actin, were: sense TTG TTA CCA ACT GGG GAC GAT A, antisense TCG TCC TTC TAG TTC TAG (bp 265 to 1028, 764-bp).
In vitro cell growth kinetics
To assess in vitro cell proliferation, subcon¯uent proliferating cultures of two clones of each clonal type were harvested using trypsin. The cells were inoculated into six-well dishes at 3610 4 cells per well in 5.0 ml of complete growth medium (DMEM plus 5% fetal calf serum) on Day 0. For each clone tested, duplicate wells were counted by hemacytometer on Days 1 ± 8. The duplicate cell counts agreed to within +5% of the mean values.
In vivo tumor growth
For each cell clone type tested, subcon¯uent proliferating cells were harvested; and a cell suspension containing 3610 6 cells in 0.15 ml of a 50 : 50 mixture of DMEM plus Matrigel (Collaborative Research) was prepared. Four-to six-week-old male athymic nude mice were injected subcutaneously with 3610 6 cells per injection, two injections per animal (on the right and left sides), 10 animals per cell clone, and two cell clones per clonal type (=20 injections per clonal type). Tumor volumes were measured twice per week by determining three mutually perpendicular diameters using calipers. Since the two individual clones of each type gave a very similar distribution of tumor sizes, these data were pooled for analysis of tumor sizes.
The volumes of the individual tumors were calculated according to the formula V (in mm 
Drug treatments
Subcon¯uent proliferating cells were exposed to the indicated dosage of drug: DNA topoisomerase IIa inhibitor adriamycin (ADR), topoisomerase I inhibitor camptothecin (CPT), or sham treatment (negative control) for either 2 or 24 h in complete culture medium. Cells were then washed to remove the drug and post-incubated in fresh drug-free culture medium for 24 h for apoptosis assays and 48 h for MTT cell viability assays.
MTT assay of cell viability
MTT assays are based on the ability of viable cells to convert MTT, a soluble tetrazolium salt (thioazyl blue) into an insoluble formazan precipitate, which is quantitated by spectrophotometry following solubilization in dimethyl sulfoxide (Fan et al., 1998; Alley et al., 1988) . Brie¯y, subcon¯uent proliferating cells in 96-well dishes were treated with cytotoxic drug in standard growth medium, washed vigorously to remove the drug, and then post-incubated for 48 h in fresh drug-free culture medium. At this time, the cells were solubilized and absorbance readings were taken using a Dynatech 96-well spectrophotometer. The amount of MTT dye reduction was calculated based on the dierence between absorbance at 570 and at 630 nm. Cell viability was expressed as the amount of dye reduction relative to that of untreated control cells. Ten replicate wells were tested per assay condition, and each experiment was repeated at least twice. Representative experiments are shown.
Apoptosis assays
Exponentially growing cells in 100 mm plastic Petri dishes were treated+drug in standard growth medium; washed twice to remove the drug; post-incubated in fresh drug-free medium for 24 h; and counted. The samples were normalized by cell number (500 000 ± 750 000 cells); and the low molecular weight apoptotic DNA was extracted, as described before (Fan et al., 1998; Herrmann et al., 1994) . The DNA was electrophoresed through 1.2% formaldehyde-agarose gels containing 0.1 mg/ml of ethidium bromide; and the gels were photographed under ultraviolet illumination.
Immunoprecipitation (IP)
Subcon¯uent proliferating cells in 150 cm 2 dishes were harvested, and nuclear extracts were prepared, as described earlier (Dignam et al., 1983) . Each IP was carried out using 6 mg of antibody or antibody combination and 1000 mg of nuclear extract protein. Precipitated proteins were collected using protein G beads, washed, eluted in boiling Laemmli sample buer, and subjected to Western blotting. The BRCA1 IP antibody was as follows: combination of Ab-1 (MS110, Cat. #OP92)+Ab-2 (MS13, Cat. #OP93)+Ab-3 (SG11, Cat. #OP94), mouse monoclonals, Oncogene Research Products/Calbiochem (Cambridge, MA, USA). The control IP antibodies were: normal mouse IgG or an irrelevant monoclonal (23C2) raised against hepatocyte growth factor/scatter factor (Grant et al., 1993) .
Western blotting
Western blotting assays were performed as described earlier (Fan et al., 1998) . Equal aliquots of protein extract (50 mg per lane) were electrophoresed on SDS-polyacrylamide gradient gels, transferred to nitrocellulose membranes (Millipore, Bedford, MA, USA), and blotted as described earlier (Fan et al., 1998) . The appropriate secondary antibodies (see below) were used at a dilution of 1 : 3000. Blotted proteins were visualized using the enhanced chemiluminescence system (Amersham Life Sciences, Arlington Heights, IL, USA), with colored markers (Bio-Rad Laboratories, Hercules, CA, USA) as molecular size standards. The protein bands were quantitated by densitometry; and the values were expressed relative to the 43 kDa a-actin band as a control for loading and transfer.
The following primary antibodies for Western blotting were obtained from Santa Cruz Biotechnology, Inc.: BRCA1 (C-20, rabbit polyclonal IgG, 1 : 200 dilution), RB (C-15-G, goat polyclonal IgG, 1 : 500 dilution; or IF8, mouse monoclonal IgG 1 , 1 : 200 dilution), p107 (SD9, mouse monoclonal IgG 1 , 1 : 150 dilution), p130 (C-20, rabbit polyclonal IgG, 1 : 200 dilution), and a-actin (I-19, goat polyclonal IgG, 1 : 500 dilution). The antibodies against the three family proteins do not cross-react with each other. The sources and dilutions for all other antibodies (p300, BRCA2, Mdm-2, p21
Waf1/Cip1 , Bcl-2, and Bax) were the same as described in an earlier publication (Fan et al., 1998) .
Confocal laser scanning microscope analysis
MCF-7 cells cultured in an 8-well Lab-Tek chamber slide (Nunc, Naperville, IL, USA) in 0.5 ml of culture medium. The cells were ®xed for 8 min at 378C with freshly prepared 3.7% paraformaldehyde in ®xation buer (274 mM NaCl, 10 mM PIPES, 4 mM EGTA, 11 mM glucose in phosphate buer). The ®xation was followed by two rinses with Trisbuered saline (TBS)/glycine. The cells were permeabilized at room temperature with 0.5% Triton X-100 in ®xation buer for 20 min and then washed three times with TBS for 5 min each. Samples were blocked with 1% goat serum and 2% BSA in TBS at room temperature for 30 min. Cells were incubated with primary antibody (see below), diluted with block solution in a humidity chamber at 378C for 20 min, or room temperature for 60 min, rinsed and then incubated with second antibody conjugated with Alexa Fluor using the same conditions as the primary antibody binding reaction.
The primary antibodies were as follows: (1) anti-BRCA1 (MS13, MS 110 mouse monoclonal, kindly provided by Dr Ralph Scully, Dana-Farber Cancer Institute, Boston, MA, USA); (2) anti-Rb (C-15, rabbit polyclonal IgG, Santa Cruz); or (3) anti-glucocorticoid receptor [GR] (M-20, rabbit polyclonal IgG, Santa Cruz). The secondary antibodies were goat anti-mouse IgG conjugated to Alexa Fluor 488 TM (green) and goat anti-rabbit IgG conjugated to Alexa Fluor 546 TM (red) (Molecular Probes Corporation). The cells were then washed twice with phosphate-buered saline; and coverslips were applied using Gel/Mount (Biomeda, Foster City, CA, USA). After immunocytochemical staining, the cells were examined with a NIKON confocal laser¯uores-cence inverted microscope with objective lenses (660 with oil) (LSM 410, Carl Zeiss, Oberkochen, Germany) using simultaneous lasers with excitation wavelengths of 543 and 488 nm for red and green, respectively, and detection using red and green narrow band ®lters. Images were collected through the specimens every 2 mm in the vertical plane, overlaid to generate focus composite images, and stored as TIFF ®les. Figures were assembled from the TIFF ®les using Adobe Photoshop software.
Glutathione-S-transferase (GST) capture assays GST capture assays were performed essentially as described earlier (Wang et al., 1993) .
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S-methionine-labeled proteins were prepared by in vitro transcription and translation, using the T7 promoter of the pcDNA3 vector. The GST fusion proteins were generated from cDNAs cloned into the GST vector (p-GEX), expressed in E. coli, and puri®ed by anity chromatography. In vitro translated labeled proteins were incubated with either GST alone (negative control) or GST fusion proteins for 4 h at 48C, recovered using GSH agarose beads, eluted in boiling Laemmli sample buer, and analysed by SDS ± PAGE autoradiography. To con®rm their expression, the GST fusion proteins were visualized by Western blotting, using an anti-GST mouse monoclonal antibody (B-14, Santa Cruz, 1 : 10 000 dilution).
Cell cycle analysis
Asynchronously proliferating cells were harvested and ®xed in 70% alcohol overnight. The cells were washed in phosphate-buered saline and resuspended for 30 min in a staining solution, containing propidium iodide (50 mg/ml) and RNase (50 mg/ml). Flow cytometric analysis (FACS) was performed using a Becton-Dickinson FACScan instrument using CellQuest software, as previously described (Fan et al., 1994) .
